Pazopanib ( DrugBank: Pazopanib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 227 | オスラー病 | 2 |
227. オスラー病
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03850730 (ClinicalTrials.gov) | July 1, 2023 | 12/2/2019 | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Pazopanib | Cure HHT | University of North Carolina | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 1/Phase 2 | NULL |
| 2 | NCT03850964 (ClinicalTrials.gov) | December 1, 2022 | 12/2/2019 | Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) | A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia | Hereditary Hemorrhagic Telangiectasia;Epistaxis;Anemia;Nosebleed;HHT | Drug: Pazopanib;Drug: Placebo oral capsule | Cure HHT | United States Department of Defense | Not yet recruiting | 18 Years | 80 Years | All | 70 | Phase 2/Phase 3 | NULL |